drugset
drugset / Trial / NCT01081756

A Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)

NCT01081756 ↗

Phase 3 Completed 218 enrolled Merck KGaA, Darmstadt, Germany
RandomizedParallel-groupOpen-labelTreatment

Summary

This was an open, randomized, comparative study using rhCG (Ovidrel) in the induction of final follicle maturation and early luteinization in Chinese female subjects undergoing IVF or ET.

Timeline

Start
2003-12
Primary completion
—
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant Human Chorionic Gonadotrophin Protein / enzyme biologic 250 ug Subcutaneous
Subject Recombinant Human Chorionic Gonadotrophin Protein / enzyme biologic 500 ug Subcutaneous
Subject Recombinant Human Chorionic Gonadotrophin Protein / enzyme biologic 750 ug Subcutaneous
Subject human chorionic gonadotropin Protein / enzyme biologic 10000 iu Subcutaneous

Indications

female infertility